Info

Plantacor, Inc. is a specialty biopharmaceutical company engaged in the development of therapeutic drugs for the treatment of cancer and other human diseases. The Company's strategy is to fill the developmental gap between basic institutional research and clinical development by addressing manufacturing challenges, preparing formulations and solutions, completing preclinical work, filing Investigational New Drug (IND) applications and entering human clinical trials with lead product candidates. We are currently focused on several novel compounds from a library of over 100 compounds, all developed by Dr. Stephen Safe at the Institute of Biosciences and Technology, Texas A&M University, in Houston, Texas. These unique analogs are derived from a natural compound found in plants known for its chemo preventative properties and are protected by a series of issued and pending patents. Efficacy testing demonstrates that CDIM-9, our lead compound, has confirmed invivo activity for arresting tumor growth in MDA-MB-231 breast cancer cells- the test model for Basal-like breast cancer. This recently identified breast cancer sub-type is very aggressive and typically targets young, pre-menopausal women and has no currently approved targeted therapy available. To fully evaluate the potential of our compounds we have developed two unique formulations, one designed for oral delivery and the other for parenteral (IV, IP, IM, subcutaneous, etc.) delivery; both assure solubility and bioavailability of the compounds formulated. This formulation and development work is the key to the success we have experienced in advancing our first drug candidates. We have five compounds-including CDIM-9, in stable formulations, fully solubilized and ready to complete the preclinical path to human clinical trials. Plantacor is achieving its goal of filling the developmental gap with the first five compounds of our TAMU library formulated and in preclinical testing with CDIM-9 poised to enter human clinical trials in late 2008.